Regeneron Pharmaceuticals, Inc. (REGN) Reports Fourth Quarter and Full Year 2012 Financial and Operating Results  
2/14/2013 7:27:06 AM

TARRYTOWN, N.Y., Feb. 14, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial and operating results for the fourth quarter and full year 2012 and provided an update on development programs.

The Company reported total revenues of $415 million in the fourth quarter and $1.4 billion for the year ended December 31, 2012. Total revenues included EYLEA U.S. net product sales of $276 million in the fourth quarter and $838 million for the full year 2012.